Patents by Inventor Ulrich Reinhold
Ulrich Reinhold has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8333990Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.Type: GrantFiled: September 13, 2010Date of Patent: December 18, 2012Assignee: Abbott LaboratoriesInventors: Joerg Rosenberg, Ulrich Reinhold, Bernd Liepold, Gunther Berndl, Joerg Breitenbach, Laman Alani, Soumojeet Ghosh
-
Patent number: 8309613Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.Type: GrantFiled: September 13, 2010Date of Patent: November 13, 2012Assignee: AbbVie Inc.Inventors: Joerg Rosenberg, Ulrich Reinhold, Bernd Liepold, Gunther Berndl, Joerg Breitenbach, Laman Alani, Soumojeet Ghosh
-
Patent number: 8268349Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.Type: GrantFiled: April 18, 2012Date of Patent: September 18, 2012Assignee: Abbott LaboratoriesInventors: Joerg Rosenberg, Ulrich Reinhold, Bernd Liepold, Gunther Berndl, Joerg Breitenbach, Laman Alani, Soumojeet Ghosh
-
Publication number: 20120225950Abstract: A semisolid aqueous pharmaceutical composition containing tapentadol or a physiologically acceptable salt thereof.Type: ApplicationFiled: March 2, 2012Publication date: September 6, 2012Applicant: Gruenenthal GmbHInventors: Ulrich REINHOLD, Marc SCHILLER, Eva WULSTEN, Sabine Karine Katrien INGHELBRECHT, Roger Carolus Augusta EMBRECHTS
-
Publication number: 20120202858Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.Type: ApplicationFiled: April 18, 2012Publication date: August 9, 2012Applicant: ABBOTT LABORATORIESInventors: Jöerg Rosenberg, Ulrich Reinhold, Bernd Liepold, Gunther Berndl, Jörg Breitenbach, Laman L. Alani, Soumojeet Ghosh
-
Publication number: 20120022089Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.Type: ApplicationFiled: September 22, 2011Publication date: January 26, 2012Applicant: ABBOTT LABORATORIESInventors: Jöerg Rosenberg, Ulrich Reinhold, Bernd Liepold, Gunther Berndl, Jörg Breitenbach, Laman L. Alani, Soumojeet Ghosh
-
Patent number: 8025899Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.Type: GrantFiled: August 25, 2004Date of Patent: September 27, 2011Assignee: Abbott LaboratoriesInventors: Gunther Berndl, Joerg Rosenberg, Bernd Liepold, Joerg Breitenbach, Ulrich Reinhold, Laman Alani, Soumojeet Ghosh
-
Publication number: 20110015216Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.Type: ApplicationFiled: September 13, 2010Publication date: January 20, 2011Applicant: ABBOTT LABORATORIESInventors: Gunther Berndl, Joerg Rosenberg, Bernd Liepold, Joerg Breitenbach, Ulrich Reinhold, Laman Alani, Soumojeet Ghosh
-
Publication number: 20110008430Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.Type: ApplicationFiled: September 13, 2010Publication date: January 13, 2011Applicant: ABBOTT LABORATORIESInventors: Jorg Rosenberg, Ulrich Reinhold, Bernd Liepold, Gunther Berndl, Jorg Breitenbach, Laman L. Alani, Soumojeet Ghosh
-
Publication number: 20080299203Abstract: The present invention provides a pharmaceutical dosage formulation, and more particularly, a pharmaceutical dosage formulation comprising an HIV protease inhibitor.Type: ApplicationFiled: August 12, 2008Publication date: December 4, 2008Inventors: Joerg Rosenberg, Ulrich Reinhold, Bernd Liepold, Gunther Berndl, Jorg Breitenbach, Laman L. Alani, Soumojeet Ghosh
-
Publication number: 20070249643Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.Type: ApplicationFiled: July 3, 2007Publication date: October 25, 2007Inventors: Joerg Rosenberg, Ulrich Reinhold, Bernd Liepold, Gunther Berndl, Jorg Breitenbach, Laman Alani, Soumojeet Ghosh
-
Publication number: 20050143404Abstract: The present invention provides a pharmaceutical dosage formulation, and more particularly, to a pharmaceutical dosage formulation comprising an HIV protease inhibitor.Type: ApplicationFiled: February 23, 2005Publication date: June 30, 2005Inventors: Joerg Rosenberg, Ulrich Reinhold, Bernd Liepold, Gunther Berndl, Jorg Breitenbach, Laman Alani, Soumojeet Ghosh
-
Publication number: 20050084529Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.Type: ApplicationFiled: August 25, 2004Publication date: April 21, 2005Inventors: Joerg Rosenberg, Ulrich Reinhold, Bernd Liepold, Gunther Berndl, Jorg Breitenbach, Laman Alani, Soumojeet Ghosh
-
Publication number: 20050048112Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.Type: ApplicationFiled: August 28, 2003Publication date: March 3, 2005Inventors: Jorg Breitenbach, Laman Alani, Gunther Berndl, Soumojeet Ghosh, Bernd Liepold, Ulrich Reinhold, Joerg Rosenberg
-
Patent number: 6547997Abstract: Solvent-free noncrystalline bioactive substances are prepared from the corresponding crystalline bioactive substances in an extruder by melting the substances in the extruder under reduced pressure and in the absence of auxiliaries, cooling and comminuting.Type: GrantFiled: May 11, 2000Date of Patent: April 15, 2003Assignee: Abbot LaboratoriesInventors: Jörg Breitenbach, Ulrich Reinhold, Jürgen Zeidler, Jörg Rosenberg
-
Patent number: 6423256Abstract: A process for producing solid dosage forms, in which (i) a plastic mixture of at least one pharmacologically acceptable polymeric binder with a K value of more than 75, at least one pharmaceutical active ingredient and, where appropriate, conventional pharmaceutical additives is prepared and (ii) the plastic mixture is shaped to the required dosage form, with step (i) being carried out under conditions of temperature and shear energy input such that the reduction in molecular weight of the polymeric binder, expressed as the difference in the K value, is less than 15 is described.Type: GrantFiled: October 13, 1999Date of Patent: July 23, 2002Assignee: BASF AktiengesellschaftInventors: Stephan Kothrade, Jörg Breitenbach, Harald Krull, Thomas Kessler, Armin Lange, Werner Maier, Ulrich Reinhold